Osborne Clarke advises naturalX Health Ventures on investment in Jutro Medical

Osborne Clarke advised consumer health investor naturalX Health Ventures on its investment in Polish healthtech company Jutro Medical. The transaction involved an extension of Jutro Medical's Series A funding round. The round was led by Warsaw Equity Group and, in addition to naturalX Health Ventures, included participation from Vinci, Fluent Ventures, Aternus, KAYA VC and Inovo VC. The financing package also comprises a debt component provided by mBank and Orbit Capital. The Series A funding volume has increased to EUR 36 million as a result of the extension. Jutro Medical, headquartered in Warsaw, is an AI-first primary care provider that integrates digital and physical care. Founded in 2020 by Adam Janczewski, the company has developed its own electronic health records (EHR) system, standardised clinic processes and AI-based tools to support documentation and patient intake. Pursuing a roll-up strategy in general practice, Jutro acquires existing practices and integrates them into a unified operating and technology platform featuring a shared EHR, standardised workflows and AI support. The company added nine clinics to its network this year, targets around 20 acquisitions per year, currently provides care to approximately 120,000 patients in Poland and plans future expansion into other European markets. Osborne Clarke represented naturalX Health Ventures with a team composed by: Till‑Manuel Saur (team lead), Robert Marx (Corporate / VC), Dr Ulrike Bär (Tax), Florian Berlejung (Tax) — all Osborne Clarke Germany; and Rafal Kozlowski (Corporate / VC), Dr Agnieszka Sztoldman (IP), Piotr Plachecki (IP), Adam Strzelecki (Commercial), Szymon Tyniec (VC) and Sławomir Kowalski (Data Protection) — all Osborne Clarke Poland.

Osborne Clarke advises naturalX Health Ventures on investment in Jutro Medical

Read the full story